CytoDyn appoints Jacob Lalezari as interim CEO, effective Nov 17, 2023

CytoDyn Inc.

Dr. Lalezari appointed interim CEO; Antonio Migliarese ceases interim President but remains CFO.
Dr. Lalezari to receive only minimum salary required by law; no cash bonus, equity, or severance.
CytoDyn has paid ~$1.5M to Lalezari's firm Quest Clinical Research since June 2021; $0.4M outstanding.
Board seeks permanent CEO; Lalezari expected to serve a few months to resolve clinical hold and pursue partnerships.
Dr. Lalezari previously served as interim CMO in 2020 and has advised the company for several years.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Jacob P. Lalezari, M.D.

interim CEO

CYDY · CytoDyn Inc.

Effective: 2023-11-17
Filed: November 21, 2023, 6:59 PM ET

On November 17, 2023, CytoDyn Inc., a Delaware corporation (the “Company”), entered into an employment agreement with. Jacob P. Lalezari, M.D. (the “Employment Agreement”), under which he will be employed as the Company’s interim CEO on an at-will basis, effective November 17, 2023.

Role change

Antonio Migliarese

interim President

CYDY · CytoDyn Inc.

Effective: 2023-11-17
Filed: November 21, 2023, 6:59 PM ET

Antonio Migliarese, who was appointed as interim President on May 18, 2023, ceased being interim President on November 17, 2023, but will continue in his roles of Chief Financial Officer and Treasurer, as well as serving as the Company’s principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jacob P. Lalezari, M.D. was appointed as interim CEO at CytoDyn Inc..

Action: appointed
Role: interim CEO

Exact text from the filing

On November 17, 2023, CytoDyn Inc., a Delaware corporation (the “Company”), entered into an employment agreement with. Jacob P. Lalezari, M.D. (the “Employment Agreement”), under which he will be employed as the Company’s interim CEO on an at-will basis, effective November 17, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Antonio Migliarese changed role as interim President at CytoDyn Inc..

Action: ceased
Role: interim President

Exact text from the filing

Antonio Migliarese, who was appointed as interim President on May 18, 2023, ceased being interim President on November 17, 2023, but will continue in his roles of Chief Financial Officer and Treasurer, as well as serving as the Company’s principal accounting officer.

View on SEC.gov

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-019285

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.